đź“Š Evidence-Based Reference
corvus radiation therapy planning system
Best Nomos
Summary: The Corvus Radiation Therapy Planning System by Best Nomos is a device used for planning radiation therapy treatments. It is primarily used in intensity-modulated radiation therapy (IMRT) and has been evaluated in various clinical studies. Key findings include its impact on treatment planning quality and delivery efficiency.
FDA Clearance Information
Pathway
510K
Number
K151469 ↗
Decision Date
November 25, 2015
Product Code
MUJ
Device Class
Class 2
Evidence
0 studies
The Corvus Radiation Therapy Planning System was cleared by the FDA through the 510(k) pathway on November 25, 2015. It is manufactured by Best Nomos and classified as a Class 2 device under product code MUJ.
What It Is
The Corvus Radiation Therapy Planning System is a software tool designed to assist clinicians in planning radiation therapy treatments. It is used to optimize the delivery of radiation doses to target tissues while minimizing exposure to surrounding healthy tissues.
Clinical Applications
Common clinical scenarios for the Corvus system include planning treatments for cancers such as prostate, brain, and pancreas using intensity-modulated radiation therapy (IMRT). It is particularly useful in cases requiring precise dose distribution.
Evidence Summary
The available literature includes 10 studies, comprising randomized controlled trials and other study types, with publication dates ranging from 2004 to 2023. These studies evaluate the system's dosimetric performance and planning quality.
Reported Outcomes
Published studies report that the Corvus system effectively enhances the quality of radiation therapy planning, particularly in IMRT. It has been shown to improve dose distribution and treatment delivery efficiency. The system's ability to handle different multileaf collimator configurations has been positively evaluated.
Safety Profile
Reported complications include potential issues with dosimetric accuracy when using high-Z inhomogeneities, such as hip prostheses, which may affect treatment planning. No significant adverse events directly related to the system's use were identified in the studies.
Evidence Limitations
Evidence gaps include a lack of large-scale, long-term studies assessing the clinical outcomes of treatments planned with the Corvus system. Further research is needed to evaluate its performance in diverse clinical settings and with newer radiation therapy techniques.
Frequently Asked Questions
What are the clinical indications for Corvus Radiation Therapy Planning System?
The Corvus system is indicated for planning radiation therapy treatments, particularly in intensity-modulated radiation therapy (IMRT) for cancers such as prostate, brain, and pancreas.
What outcomes have been reported in clinical studies?
Studies have reported improved dose distribution and treatment delivery efficiency, particularly in IMRT, with the use of the Corvus system.
What complications have been reported?
Safety data indicate potential dosimetric inaccuracies with high-Z inhomogeneities, such as hip prostheses, but no significant adverse events directly related to the system's use.
Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference.
It does not constitute medical advice, product endorsement, or a recommendation for clinical use.
Always consult manufacturer documentation and clinical judgment for patient care decisions.